Emerging Markets A Growth Pillar As Takeda Seeks Turnaround
This article was originally published in PharmAsia News
Executive Summary
Emerging markets were one of Takeda's main growth drivers in a fiscal first half with which the company says it was "very pleased" as it seeks to return to sustainable growth and profitability despite the challenges of patent losses that hit its performance in some major markets.
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
PMDA Eyes More Japan-First Approvals In Access Push
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Quick Listen: Scrip’s Five Must-Know Things
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Need a specific report? 1000+ reports available
Buy Reports